Novo Nordisk, the Danish drugmaker behind the popular obesity drug Wegovy, warns of fierce competition and market pressures, potentially leading to layoffs. As compounders produce cheaper copycats, U.

The shrinking ranks of "Dividend Knight" contenders. Healthcare stocks with hard times but high yields. What investors should ...

The maker of Ozempic and Wegovy has declared war on “fake” copycat weight-loss jabs as it battles a sales slowdown.

Novo Nordisk faces a sharp decline in sales of its injectable diabetes drugs, including Ozempic, due to intense competition ...

Stock index futures were higher on Wednesday, a day after Wall Street closed in the red, driven by disappointing economic ...

Copenhagen: Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second quarter net profit Wednesday, but rising ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly, ...

Novo Nordisk is facing a sharp decline in sales of its injectable diabetes drugs, including Ozempic, due to increased competition and potential US tariffs.